ABSTRACT
Chimeric antigen receptor (CAR)-redirected cellular therapy is an attractive modality for cancer treatment. We hypothesized that allogeneic CAR-engineered CD45RA-negative T cells can control cancer and infection without the risk of graft-versus-host disease (GVHD). We used CD19(+) MLL-rearranged leukemia as prototype because it is an aggressive and generally drug-resistant malignancy. CD45RA(-) cells that were transduced with anti-CD19 CAR containing 4-1BB and CD3ζ signaling domains effectively lysed MLL-rearranged leukemia cell lines and primary blasts in vitro. In a disseminated leukemia mouse model, CAR(+)CD45RA(-) cells significantly reduced leukemia burdens and prolonged overall survival without GVHD. CAR(+) cells were sustainable in blood, and all the treated mice remained leukemia-free even after they were re-challenged with leukemia cells. Despite the transduction process, CD45RA(-) cells retained recall activity both in vitro and in vivo against human pathogens commonly found in cancer patients. In comparison with CD45RA(+) cells, CD45RA(-) cells showed less allogeneic activity in mixed leukocyte reactions and in mouse models. Thus, the use of CAR(+)CD45RA(-) cells can separate GVHD from graft-versus-malignancy effect and infection control. These cells should also be useful in nontransplant settings and may be administered as off-the-shelf third-party cells.
Subject(s)
Graft vs Host Disease/immunology , Leukemia/blood , Leukocyte Common Antigens/metabolism , T-Lymphocytes/cytology , Animals , Antigens, CD19/metabolism , Cell Line, Tumor , Drug Resistance , Drug Resistance, Neoplasm , Flow Cytometry , Histone-Lysine N-Methyltransferase , Humans , Immunologic Memory , Leukemia/immunology , Leukemia/metabolism , Leukocytes, Mononuclear/cytology , Mice , Myeloid-Lymphoid Leukemia Protein/genetics , Neoplasms/metabolism , Receptors, Antigen/metabolism , Recurrence , Signal TransductionABSTRACT
Haemophilus ducreyi expresses several putative virulence factors in vitro. Isogenic mutant-to-parent comparisons have been performed in a human model of experimental infection to examine whether specific gene products are involved in pathogenesis. Several mutants (momp, ftpA, losB, lst, cdtC, and hhdB) were as virulent as the parent in the human model, suggesting that their gene products did not play a major role in pustule formation. However, we could not exclude the possibility that the gene of interest was not expressed during the initial stages of infection. Biopsies of pustules obtained from volunteers infected with H. ducreyi were subjected to reverse transcription-PCR. Transcripts corresponding to momp, ftpA, losB, lst, cdtB, and hhdA were expressed in vivo. In addition, transcripts for other putative virulence determinants such as ompA2, tdhA, lspA1, and lspA2 were detected in the biopsies. These results indicate that although several candidate virulence determinants are expressed during experimental infection, they do not have a major role in the initial stages of pathogenesis.
Subject(s)
Chancroid/microbiology , Haemophilus ducreyi/genetics , Haemophilus ducreyi/pathogenicity , RNA, Bacterial/biosynthesis , RNA, Messenger/biosynthesis , Adult , Female , Genes, Bacterial , Humans , Male , Reverse Transcriptase Polymerase Chain Reaction , Transcription, Genetic , Virulence/geneticsABSTRACT
Haemophilus ducreyi produces an outer membrane protein called DsrA, which is required for serum resistance. An isogenic dsrA mutant, FX517, was constructed previously in H. ducreyi 35000. Compared to its parent, FX517 cannot survive in normal human serum. When complemented in trans with a plasmid containing dsrA, FX517 is converted to a serum-resistant phenotype (C. Elkins, K. J. Morrow, Jr., and B. Olsen, Infect. Immun. 68:1608-1619, 2000). To test whether dsrA was transcribed in vivo, we successfully amplified transcripts in five biopsies obtained from four experimentally infected human subjects. To test whether DsrA was required for virulence, six volunteers were experimentally infected with 35000 and FX517 and observed for papule and pustule formation. Each subject was inoculated with two doses (70 to 80 CFU) of live 35000 and 1 dose of heat-killed bacteria on one arm and with three doses (ranging from 35 to 800 CFU) of live FX517 on the other arm. Papules developed at similar rates at sites inoculated with the mutant or parent. However, mutant papule surface areas were significantly smaller than parent papules. The pustule formation rate was 58% (95% confidence interval [CI] of 28 to 85%) at 12 parent sites, and 0% (95% CI of 0 to 15%) at 18 mutant sites (P = 0.0004). Although biosafety regulations precluded our testing the complemented mutant in humans, these results suggest that expression of DsrA facilitates the ability of H. ducreyi to progress to the pustular stage of disease.
Subject(s)
Bacterial Outer Membrane Proteins/genetics , Chancroid/etiology , Haemophilus ducreyi/pathogenicity , Mutation , Adult , Biopsy , Chloramphenicol/pharmacology , Female , Haemophilus ducreyi/genetics , Haemophilus ducreyi/isolation & purification , Humans , Male , Microbial Sensitivity TestsABSTRACT
PURPOSE: Treatment designed to eliminate thrombus in patients with iliofemoral deep venous thrombosis (DVT) is theoretically attractive; however, its benefits, compared with those of anticoagulation, have not been definitively demonstrated. Although not previously analyzed, an effective measure of treatment success is likely to be the assessment of health-related quality of life (HRQOL). This study evaluated whether catheter-directed thrombolysis for iliofemoral DVT is associated with improved HRQOL, compared with standard anticoagulation, and whether HRQOL outcome in the thrombolysis group is related to lytic success. METHODS: An 80-item self-administered HRQOL questionnaire was developed. It contained the Health Utilities Index, Short Form-12, and disease-targeted scales, including health distress, stigma, health interference, physical functioning, and symptoms (eg, leg swelling, pain, ulcers). The HRQOL questionnaire was confirmed to be reliable and valid by means of psychometric testing. Questionnaires were administered to 98 retrospectively identified patients who had had iliofemoral DVT treated at least 6 months earlier. Sixty-eight patients who were identified through a DVT registry were treated with catheter-directed thrombolysis with urokinase (UK), and 30 patients who were identified by means of a medical record review were treated with anticoagulation alone. The treatment decision was made by the attending physician, and all patients were candidates for both thrombolysis and anticoagulation. RESULTS: Most patients were women (61%), white (95%), married (65%), and had a mean interval since initial DVT of 16 months. The group treated with UK was younger (53 +/- 17 years) than the group treated with heparin (61 +/- 6 years; P =.039). After treatment, patients treated with UK reported better overall physical functioning (P =.046), less stigma (P =.033), less health distress (P =.022), and fewer post-thrombotic symptoms (P =. 006), compared with the patients treated with anticoagulation alone. Within the UK group, phlebographically successful lysis correlated with improved HRQOL (P =.038). Patients classified as lytic failures had similar outcomes to patients treated with heparin. CONCLUSION: Patients with iliofemoral DVT treated with catheter-directed thrombolysis have better functioning and well-being, compared with patients treated with anticoagulation alone. Successful lysis was directly correlated with improved HRQOL, with patients who were classified as lytic failures having similar outcomes to patients treated with heparin. These data support the need for a future randomized trial, which should include an HRQOL measure as part of the outcome analysis.
Subject(s)
Plasminogen Activators/therapeutic use , Quality of Life , Thrombolytic Therapy , Urokinase-Type Plasminogen Activator/therapeutic use , Venous Thrombosis/drug therapy , Aged , Anticoagulants/therapeutic use , Female , Femoral Vein , Health Status Indicators , Heparin/therapeutic use , Humans , Iliac Vein , Male , Middle AgedABSTRACT
Haemophilus ducreyi expresses 2 OmpA homologs, designated MOMP and OmpA2, whose genes are arranged in tandem on the chromosome. Northern blot analysis indicated that momp and ompA2 are transcribed independently. Sequences of the momp open reading frame (ORF) lacking the transcriptional start site were amplified by PCR, and an Omega-Km2 cassette was ligated into the ORF. A plasmid containing this construction was electroporated into H. ducreyi 35000HP, and an isogenic MOMP-deficient mutant (35000HP-SMS2) was generated by allele exchange. In Southern blotting, 35000HP-SMS2 contained one copy of the Omega-Km2 cassette in momp. 35000HP and 35000HP-SMS2 had similar outer membrane protein (OMP) and lipooligosaccharide profiles and growth rates except for up-regulation of a putative porin protein in the mutant. Five subjects were inoculated with three doses of live 35000HP-SMS2 on one arm and two doses of live 35000HP and one dose of a heat-killed control on the other arm in a double-blind escalating dose-response trial. Pustules developed at 7 of 10 sites inoculated with 35000HP and at 6 of 15 sites inoculated with 35000HP-SMS2 (P = 0.14). 35000HP and 35000HP-SMS2 were recovered at similar rates from daily surface cultures and semiquantitative cultures. The data suggest that expression of MOMP is not required for pustule formation by H. ducreyi in the human model of infection.
Subject(s)
Bacterial Outer Membrane Proteins/physiology , Haemophilus ducreyi/pathogenicity , Adult , Amino Acid Sequence , Bacterial Outer Membrane Proteins/genetics , Chancroid/immunology , Chancroid/microbiology , Chancroid/pathology , Female , Gene Deletion , Haemophilus ducreyi/genetics , Haemophilus ducreyi/immunology , Humans , Models, Biological , Molecular Sequence Data , Phenotype , Transcription, GeneticABSTRACT
OBJECTIVE: This study was designed to evaluate the safety and regional and systemic effects of three doses of urokinase (UK) infused into the distal arterial circulation during routine operative lower extremity revascularization. METHODS: One hundred thirty-four patients were prospectively randomized to receive one of three bolus doses of UK (125,000, 250,000, or 500,000 U) or placebo (saline) infused into the distal circulation before lower extremity bypass for chronic limb ischemia. Regional (femoral vein) and systemic (arm) blood was sampled before drug infusion, prereperfusion, and postreperfusion, and systemic blood samples were obtained 2 hours postreperfusion. Assays evaluated plasma levels of fibrinogen, fibrin(ogen) degradation products (FDP), fibrin breakdown products (D-dimer and fragment B-beta 15-42), and plasminogen. Patients were monitored for clinically evident bleeding complications. The Wilcoxon rank-sum test was used to compare different drug doses with the placebo. RESULTS: Intraoperative bolus UK infusions produced no significant fibrinogen breakdown compared with placebo. There was a dose-related decline in plasminogen levels, which became significant at a dose of 500,000 U of UK (p < 0.001). There were dose-related increases in plasma FDP, which became significant at dose of 250,000 and 500,000 U (p < or = 0.005), and in plasma D-dimer, which were significant at all UK doses (p < 0.001). The changes in plasma fibrinogen and markers of fibrin breakdown were similar in the regional and systemic circulations. There was no increase in operative blood loss, blood replaced, or wound hematoma formation. There was an unexplained increased mortality in the placebo group (21.1% vs. 2.0%, p = 0.033). CONCLUSIONS: Intraoperative bolus UK infusion is safe, with no significant fibrinogen depletion or increased operative blood loss or wound hematoma formation. Dose-related plasminogen activation resulted in significant breakdown in cross-linked fibrin in the distal circulation. Intraoperative bolus UK infusion may be valuable as an adjunct in patients with chronic occlusive disease who are undergoing revascularization. Detailed randomized studies are indicated to establish clinical efficacy.
Subject(s)
Intraoperative Care , Ischemia/drug therapy , Leg/blood supply , Urokinase-Type Plasminogen Activator/administration & dosage , Aged , Chronic Disease , Combined Modality Therapy , Dose-Response Relationship, Drug , Female , Fibrinogen/drug effects , Humans , Infusions, Intra-Arterial , Ischemia/surgery , Male , Middle Aged , Plasminogen/drug effects , Postoperative Complications/mortality , Prospective Studies , Single-Blind MethodABSTRACT
Sixty-four fish were blast-frozen to -35 C for 15 hr to determine the effects of commercial blast-freezing on the viability of third-stage larvae of Anisakis simplex encapsulated in the muscle and viscera of sockeye salmon (Oncorhynchus nerka) and canary rockfish (Sebastes pinniger). Parallel tests were conducted on larval nematodes in 16 whole (round) salmon, 16 dressed salmon (heads and viscera removed), and 32 whole (round) rockfish. After blast-freezing, 4 in-the-round salmon, 4 dressed salmon, and 8 in-the-round rockfish were examined at 1, 24, 48, and 72 hr. A total of 3,539 dead and 6 live larvae were collected from the fish tissues after standard enzymatic digestion. Salmon were infected with 1,245 of these larvae, and rockfish with 2,300. The 6 live worms, 2 from salmon and 4 from rockfish rounds, were recovered from muscle 1 hr after freezing; they were slightly motile and showed severe internal damage. No viable worms were found at or after 24 hr. The commercial blast-freezing process effectively killed larval nematodes in whole or dressed fish. Market-ready samples of previously blast-frozen silver salmon (O. kisutch) and chum salmon (O. keta) fillets and chum salmon steaks yielded no live worms, thereby confirming the efficacy of this process.
Subject(s)
Fishes/parasitology , Food Contamination , Food Handling , Nematoda/growth & development , Nematode Infections/prevention & control , Animals , Freezing , Humans , Larva , Salmon/parasitologyABSTRACT
A growth detection method utilizing an automated apparatus capable of rapidly detecting bacterial growth by measuring changes of electrical impedance in bacteriological medium was utilized with "mock" blood cultures containing various gram-negative and gram-positive bacteria. Measurement of changes of electrical impedance was found to ba as accurate and comparable for time of growth detection as the radiometric method for detection of the same bacteria using mock blood cultures. In a limited clinical trial the use of the electrical impedance apparatus detected in 1 positive specimen from 40 clinical blood specimens as rapidly as by radiometric measurement. Both methods were considerably faster for detecting bacterial growth as compared with conventional culture methods. The selected species of gram-positive and -negative organisms tested were all detected by the electrical impedance method, including aerobes and anerobes. However, addition of 5% CO2 to the incubation atmosphere enhanced detection of gram-positive organisms.
Subject(s)
Bacteria/isolation & purification , Bacteriological Techniques , Blood/microbiology , Sepsis/diagnosis , Aerobiosis , Anaerobiosis , Bacteria/growth & development , Bacteriological Techniques/instrumentation , Carbon Radioisotopes , Culture Media , Diagnosis, Differential , Electric Conductivity , HumansABSTRACT
An apparatus capable of rapidly detecting changes in electrical impedance was utilized for the continuous monitoring of bacterial growth in routine urine specimens in a clinical laboratory. In a trial study, 200 clinical specimens analyzed by the electrical impedance method resulted in an average detection time of 2.5 h for 41 clinically significant specimens, whereas conventional methods for bacterial isolation required overnight culture. Those specimens positive by the electrical impedance monitoring but negative by conventional bacteriological methods accounted for less than 2% of the total number of positive specimens, whereas electrical impedance-negative but conventional culture-positive specimens accounted for ca. 4%. Electrical impedance apparatus in clinical microbiology laboratories could provide rapid screening of clinical urine specimens as well as accurate detection of bacterial growth.
Subject(s)
Bacteria/growth & development , Bacteriological Techniques , Bacteriuria/diagnosis , Urine/microbiology , Bacteria/isolation & purification , Bacteriological Techniques/instrumentation , Diagnosis, Differential , Electric Conductivity , Evaluation Studies as Topic , Humans , Species SpecificityABSTRACT
A radiometric procedure for rapid detection of bacteria in clinical blood specimens was utilized over a period of 1 year in this laboratory. Although in initial studies it was felt that all positive bacteremias would be detected by radiometric examination of cultures for 14CO2 evolution over a 7-day period, we found in the present study that a significant number of bacteria were not detected, except by blind subculturing on day 7 before discarding the culture sample. Microorganisms were detected in 490 individual specimens from 348 patients after examination of 6,200 individual blood specimens, both anaerobically and aerobically. All but 30 of the positive specimens were detected by the radiometric procedure, with an average detection time of 30.5 h. Thirty organisms, representing 6% of the total organisms isolated, were not detected by the BACTEC apparatus. The predominating organisms missed by the radiometric method were group D streptococci, both enterococcal and non-enterococcal species. These isolates represented two-thirds of the total number of organisms not detected by the radiometric procedure. A majority of bacteria detected only upon terminal subculture were isolates from a very small number of patients, suggesting that these organisms might have specific properties that preclude their detection by radiometric assay. Nevertheless, our study results indicate that it is essential that all radiometrically examined blood culture specimens be subcultured prior to discard in order to lessen the likelihood of missing a microbial pathogen.